The report provides a detailed analysis essential for establishing a Mitoxantrone production plant. It encompasses all critical aspects necessary for Mitoxantrone production, including the cost of Mitoxantrone production, Mitoxantrone plant cost, Mitoxantrone production costs, and the overall Mitoxantrone production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Mitoxantrone production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Mitoxantrone is a synthetic anthracenedione chemotherapeutic agent that treats acute myeloid leukaemia (AML). It is utilised in adults as induction therapy combined with cytarabine, for hormone-refractory prostate cancer, alongside prednisone to reduce bone pain and slow progression.
It is also utilised in rapidly progressing multiple sclerosis forms, including secondary-progressive and worsening relapsing-remitting types, by reducing relapses and disability through immune suppression. It adds DNA strands, inhibits topoisomerase II to halt cancer cell replication, and exhibits lower cardiotoxicity than anthracyclines. It is suitable for patients intolerant to doxorubicin, though usage requires careful monitoring due to risks like heart failure and secondary leukemia with cumulative doses limited to around 160 mg/m².
The market for Mitoxantrone is driven by its usage in treating acute myeloid leukaemia in adults through induction therapy. Its utilisation in combination with other drugs like cytarabine and as a second-line option with prednisone contributes to its demand. Its market shows steady expansion driven by growing global cases of these cancers and multiple sclerosis. The improvements in early oncology diagnostics and broader healthcare access in developing regions, including the Asia-Pacific, fuel the market. The industrial Mitoxantrone procurement is influenced by adherence to strict regulatory standards from bodies like the FDA and EMA. The dependable supplier networks and the presence of generic versions improve availability for resource-limited settings.
Raw Material for Mitoxantrone Production
According to the Mitoxantrone production plant project report, the key raw materials used in the production of Mitoxantrone include chrysazin, nitric acid, and N-(2-hydroxyethyl)ethylenediamine.
Production Process of Mitoxantrone
The extensive Mitoxantrone production cost report consists of the following major industrial production process:
- From Chrysazin: The production process of Mitoxantrone starts with chrysazin, which is nitrated to 4,5-dinitrochrysazin. This dinitro intermediate goes through selective reduction of nitro groups to amino groups, followed by further processing to the leuco tetrahydroxyanthraquinone. This leuco base is dissolved in 1,4-dioxane under an inert atmosphere. N-(2-hydroxyethyl)ethylenediamine is added dropwise at room temperature. The mixture is poured into absolute ethanol, oxygen is bubbled through while heating until a bright blue colour develops, then cooled and stood to form blue crystals of crude Mitoxantrone. The crude product is refined by treating with activated carbon, hot filtering, cooling to crystallise, filtering, rinsing, and drying to yield pure Mitoxantrone hydrochloride.
Mitoxantrone is a dark blue to black crystalline solid at room temperature with a molecular formula of C22H28N4O6 and a molecular weight of around 444.5 g/mol. It has a planar anthracenedione core with two hydroxy groups at positions 5 and 8, aminoalkyl side chains bearing hydroxyethyl groups for DNA intercalation via hydrogen bonding. It shows low water solubility with a pKa value of around 6-8 for protonation. It has high lipophilicity reflected in a negative logP value, aiding cell membrane crossing, melting point of 203-205 degree Celsius for the dihydrochloride. Its stability requires dark, cool, dry storage to prevent degradation.